Voglibose
- Generic Name
- Voglibose
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H21NO7
- CAS Number
- 83480-29-9
- Unique Ingredient Identifier
- S77P977AG8
- Background
Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix.
- Indication
For the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.
- Associated Conditions
- Hyperglycemia, Postprandial, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- Glycemic Control
Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2014-04-08
- Target Recruit Count
- 30
- Registration Number
- NCT02097342
- Locations
- 🇮🇳
Postgraduate Institute of Medical Education & Research, Chandigarh, India
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 494
- Registration Number
- NCT02049814
Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 742
- Registration Number
- NCT01993927
Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01309698
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 438
- Registration Number
- NCT01263496
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
- Conditions
- Interventions
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 480
- Registration Number
- NCT01263470
Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
- Conditions
- Interventions
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 230
- Registration Number
- NCT01263483
MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
- Conditions
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 133
- Registration Number
- NCT00837577
Glufast On Insulin Glargine Trial in Type 2 DM
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2012-03-30
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 167
- Registration Number
- NCT00663884
- Locations
- 🇰🇷
The Catholic Univ. of Korea, Kangnam ST. Mary's Hospital, Seoul, Korea, Republic of
Japanese P III vs Voglibose and Placebo
- Conditions
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 561
- Registration Number
- NCT00654381
- Locations
- 🇯🇵
1218.23.33 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵1218.23.35 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵1218.23.19 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.